Understanding the Mechanism of Action of Cosibelimab in Advanced cSCC

In this video, explore the mechanism of action of cosibelimab, a PD-L1 inhibitor approved for the treatment of advanced cutaneous squamous cell carcinoma (cSCC). The video reviews how cosibelimab disrupts the interaction between PD-L1 and PD-1 on T cells, as well as its active Fc domain and its role in engaging natural killer cells and initiating antibody-dependent cellular cytotoxicity.

The video also examines how cosibelimab preserves PD-L2 signaling and reviews clinical efficacy and immune-mediated adverse reactions associated with treatment in patients with metastatic and locally advanced cSCC.